Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
5.26
-0.24 (-4.36%)
Sep 10, 2026, 11:34 AM EDT - Market open
Aligos Therapeutics Stock Forecast
ALGS's stock price has decreased by -50.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 analysts polled by S&P Global, Aligos Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $53.43. The average 1-year stock price forecast is 915.78% higher than the current stock price, while the lowest is $20 (+280.23%) and the highest is $175 (+3,227.00%).
Price Target: $53.43 (+915.78%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 10, 2026.
Analyst Ratings
The average analyst rating for Aligos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $50 | Buy | Reiterates | $50 | +850.57% | Aug 10, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $175 | Buy | Maintains | $175 | +3,227.00% | Aug 7, 2026 |
| Lake Street | Lake Street | Buy Reiterates $45 | Buy | Reiterates | $45 | +755.51% | Aug 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $20 | Buy | Maintains | $20 | +280.23% | Aug 7, 2026 |
| Jefferies | Jefferies | Buy Initiates $48 | Buy | Initiates | $48 | +812.55% | Mar 19, 2026 |
Financial Forecast
Revenue This Year
36.33M
from 2.19M
Increased by 1,562.10%
Revenue Next Year
5.43M
from 36.33M
Decreased by -85.07%
EPS This Year
-6.58
from -2.45
EPS Next Year
-5.05
from -6.58
EPS and Forward PE are based on non-GAAP adjusted numbers.